News

Jonathan Silverberg, MD, PhD, MPH, talks about when and how to take itch into consideration when choosing a therapy for AD.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Amanda Caldwell, MSN, APRN-C, is fostering community and collaboration for NPs and PAs as the new president of the SDNP.

Renata Block, PA-C, speaks with patient advocate Brittanny Groover on her experience, how to educate young patients, and understanding the psychosocial impact of melanoma.

RAPIDS 2025 captivated with expert insights on immuno-dermatology, featuring engaging sessions and lively panels.

Peter Graylin shares his transformative skin cancer journey, emphasizing the importance of early detection, sun safety, and accessible dermatology programs.

Jonathan Silverberg, MD, PhD, MPH, shares pearls from the ADvocate1 and 2 trials examining the use of lebrikizumab for AD.

A new partnership aims to revolutionize topical treatments for epidermolysis bullosa, enhancing patient care with innovative drug delivery technology.

Dermatology Times is recapping our exclusive expert interviews from the month of May.

This review of the latest dermatologic studies includes insights into psoriatic lesions and PsA, adipose mesenchymal stem cell-derived exosomes versus platelet-rich plasma, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Amanda Caldwell, MSN, APRN-C, is promoting accessibility, education, and relatability as the newly inducted president of the Society for Dermatology Nurse Practitioners.

Microneedling proves more effective than microinjections for PRP therapy in treating melasma, enhancing patient outcomes and satisfaction.

AI Medical Technology launches Dermalyser, an AI tool for melanoma diagnosis, enhancing detection accuracy and skin cancer care in Europe.

Jonathan Silverberg, MD, PhD, MPH, talks about therapies used for AD, including nemolizumab.

In March, popular acne products were recalled due to benzene contamination, raising safety concerns and highlighting the need for better quality control in skin care.

Christopher G. Bunick, MD, PhD, presents the significant challenges of CHE due to a lack of FDA-approved treatments, impacting patients' quality of life and requiring better therapeutic options.

Answer our poll below.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

LEO Pharma reveals promising phase 2b trial results for temtokibart, a treatment targeting moderate to severe atopic dermatitis effectively.

New research reveals significant racial disparities in depression risk among vitiligo patients, highlighting the need for culturally sensitive mental health support.

Sarah Allen, MD's Skin Clique has launched a virtual Esthetician Program, providing personalized skincare consultations and bridging access to expert guidance for all patients.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about the FDA's approval of Arcutis' roflumilast for plaque psoriasis, cold plasma technology for acne-prone skin, azathioprine for the long-term treatment of alopecia, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Skin care for diabetes management focuses on prevention, routine inspections, and maintaining healthy skin to avoid complications.